Explore Topics and Trends impacting today's markets

Since putting in a pandemic low on March 23, 2020, Nasdaq 100 futures have posted a stunning 125% rally in the subsequent 17 months, making an all-time high on July 26, 2021. This gain far outpaces the 100% rally of the broader S&P 500. The Nasdaq’s out performance has been generally attributed to several factors. The primary reason given for the initial gain was a belief that the pandemic and post pandemic economy would rely heavily on technology as work from home and remote communication became paramount. 

Tech's Relationship to Rates

There was also the issue of interest rates. Technology companies tend to have a strong inverse correlation to interest rates because of commonly used discounted cash flow models. In short, the lower interest rates are today, the more attractive the growth and technology sector becomes because of optimistic projections of future earnings.

Of course, this phenomenon occurs in all stocks to some extent, but it’s much more pronounced in technology.  There is another characteristic of this rally that has drawn some attention. The biggest beneficiaries have been a select few technology behemoths. At current valuations only seven companies make up almost 50% of the market cap of the entire Nasdaq index. The largest six U.S. companies by market cap and six out of the top eight global companies are among those same Nasdaq technology companies. The overall index is now more closely correlated to the price movements of a handful of companies than it has been in the past. 

The Corrections

The rally has not been without some significant hurdles. In February 2021 the Nasdaq suffered a 12% correction and again in April it lost 8% of its value. These losses occurred at or near the week when much of the technology sector reported earnings. This was interesting in that the reported earnings of the tech giants were somewhere between good and really good. Perhaps the weakness that followed was an indication of a crowded long trade or perhaps it was due to the fact that interest rates were rising concurrently in both instances.

Since April, however, the story in interest rates has changed. The collapse of several high- profile commodities has taken some wind out of the inflation narrative and has allowed the 10-year yield to go from a high of 1.7% in April to a current level of 1.2%. This development appears to be supportive of the Nasdaq in relation to the other indexes as pandemic fears rise. 

Headlines from the U.K. regarding a resumption of travel restrictions coupled with an alarming rise of new variants of COVID-19 have challenged the assumption of a smooth reopening. The question traders are asking themselves is will a backtrack of the reopening trade boost the Nasdaq as it did in the early stages of the pandemic? The next few weeks of pandemic developments could create volatility in the sector. 

Micro Nasdaq

Alongside the massive rally in tech stocks has been increases in trading volumes of Nasdaq futures, particularly the micro contracts, traded on CME. The micro e-mini contracts seem to reflect the growing involvement of retail traders with a desire to take a more active role in their financial management.

The Micro Nasdaq contract is 1/10th the size of the standard E-mini contract and currently has a notional value around $29,000. Each contract requires $1600 in maintenance margin for an 18/1 leverage ratio. This allows opportunities for risk hedging or directional expression with minimal capital tied up. The average daily volumes in Nasdaq micros has grown to near 1,000,000 contracts per day and the contract has shown impressive around the clock liquidity. 

With how widely held the biggest names in technology are and how correlated they are to the Nasdaq, micros have become a reasonable hedge against longer term equity holdings especially during these times of potential market turbulence. 



OpenMarkets is an online magazine and blog focused on global markets and economic trends. It combines feature articles, news briefs and videos with contributions from leaders in business, finance and economics in an interactive forum designed to foster conversation around the issues and ideas shaping our industry.

All examples are hypothetical interpretations of situations and are used for explanation purposes only. The views expressed in OpenMarkets articles reflect solely those of their respective authors and not necessarily those of CME Group or its affiliated institutions. OpenMarkets and the information herein should not be considered investment advice or the results of actual market experience. Neither futures trading nor swaps trading are suitable for all investors, and each involves the risk of loss. Swaps trading should only be undertaken by investors who are Eligible Contract Participants (ECPs) within the meaning of Section 1a(18) of the Commodity Exchange Act. Futures and swaps each are leveraged investments and, because only a percentage of a contract’s value is required to trade, it is possible to lose more than the amount of money deposited for either a futures or swaps position. Therefore, traders should only use funds that they can afford to lose without affecting their lifestyles and only a portion of those funds should be devoted to any one trade because traders cannot expect to profit on every trade. BrokerTec Americas LLC (“BAL”) is a registered broker-dealer with the U.S. Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (www.FINRA.org), and is a member of the Securities Investor Protection Corporation (www.SIPC.org). BAL does not provide services to private or retail customers.. In the United Kingdom, BrokerTec Europe Limited is authorised and regulated by the Financial Conduct Authority. CME Amsterdam B.V. is regulated in the Netherlands by the Dutch Authority for the Financial Markets (AFM) (www.AFM.nl). CME Investment Firm B.V. is also incorporated in the Netherlands and regulated by the Dutch Authority for the Financial Markets (AFM), as well as the Central Bank of the Netherlands (DNB).

©2024 CME Group Inc. All rights reserved